Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion

Biochemical and Biophysical Research Communications

Volumn 400, Issue 3, 2010, Pages 437-441

  Yoshida, Shigeru ^a   Ohishi, Takahide ^a   Matsui, Tetsuo ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

AS1269574; Glucose stimulated insulin secretion; GPR119; Pancreatic cell; Small molecule

Indexed keywords

2 [2 (4 BROMOPHENYL) 6 METHYLPYRIMIDIN 4 YL]AMINO ETHANOL; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AS 1269574; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; GLIBENCLAMIDE; GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT; PYRIMIDINE; UNCLASSIFIED DRUG; 2-(2-(4-BROMOPHENYL)-6-METHYLPYRIMIDIN-4-YL)AMINOETHANOL; ANTIDIABETIC AGENT; ETHANOLAMINE DERIVATIVE; GLUCOSE BLOOD LEVEL; GPR119 PROTEIN, HUMAN; GPR119 PROTEIN, MOUSE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CELL STRAIN HEK293; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; AGONISTS; ANIMAL; CELL LINE; CHEMISTRY; DIET RESTRICTION; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; ISOLATION AND PURIFICATION; PANCREAS ISLET BETA CELL; SECRETION (PROCESS);

ANIMALS; BLOOD GLUCOSE; CELL LINE; ETHANOLAMINES; FASTING; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED ICR; PYRIMIDINES; RECEPTORS, G-PROTEIN-COUPLED;

MUS;

EID: 77956936188     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.097     Document Type: Article

References (22)

1. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1999, 15:318-368.
2. Taylor S.I., Accili D., Imai Y. Insulin resistance or insulin deficiency: which is the primary cause of NIDDM?. Diabetes 1994, 43:735-740.
3. Meece J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr. Med. Res. Opin. 2007, 23:933-944.
4. Seino Y., Rasmussen M.F., Nishida T., Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs. glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr. Med. Res. Opin. 2010, 26:1013-1022.
5. Nauck M.A., Vilsbøll T., Gallwitz B., Garber A., Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009, 32(Suppl. 2):S223-S231.
6. Ahrén B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin. Emerg. Drugs 2008, 13:593-607.
7. Doupis J., Veves A. DPP4 inhibitors: a new approach in diabetes treatment. Adv. Ther. 2008, 25:627-643.
8. Chia C.W., Egan J.M. Incretin-based therapies in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2008, 93:3703-3716.
9. Soga T., Ohishi T., Matsui T., Saito T., Matsumoto M., Takasaki J., Matsumoto S., Kamohara M., Hiyama H., Yoshida S., Momose K., Ueda Y., Matsushime H., Kobori M., Furuichi K. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun. 2005, 28:744-751.
10. Sakamoto Y., Inoue H., Kawakami S., Miyawaki K., Miyamoto T., Mizuta K., Itakura M. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem. Biophys. Res. Commun. 2006, 351:474-480.
11. Overton H.A., Babbs A.J., Doel S.M., Fyfe M.C., Gardner L.S., Griffin G., Jackson H.C., Procter M.J., Rasamison C.M., Tang-Christensen M., Widdowson P.S., Williams G.M., Reynet C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006, 3:167-175.
12. Chu Z.L., Jones R.M., He H., et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007, 148:2601-2609.
13. Chu Z.L., Jones R.M., He H., Carroll C., Gutierrez V., Lucman A., Moloney M., Gao H., Mondala H., Bagnol D., Unett D., Liang Y., Demarest K., Semple G., Behan D.P., Leonard J. A role for intestinal endocrine cell-expressed GPR119 in glycemic control by enhancing GLP-1 and GIP release. Endocrinology 2008, 149:2038-2047.
14. Jones R.M., Leonard J.N., Buzard D.J., Lehmann J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 2009, 19:1339-1359.
15. Mizushima S., Nagata S. pEF-BOS: a powerful mammalian expression vector. Nucleic Acids Res. 1990, 18:5322.
16. Leiter L.A., Ceriello A., Davidson J.A., Hanefeld M., Monnier L., Owens D.R., Tajima N., Tuomilehto J. Postprandial glucose regulation: new data and new implications. Clin. Ther. 2005, 27(Suppl. B):S42-S56.
17. Woerle H.J., Neumann C., Zschau S., Tenner S., Irsigler A., Schirra J., Gerich J.E., Göke B. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res. Clin. Pract. 2007, 77:280-285.
18. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004, 64:1339-1358.
19. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat. Rev. Drug. Disc. 2009, 8:369-385.
20. Winzell M.S., Ahrén B. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. Pharmacol. Ther. 2007, 116:437-448.
21. Morgan N.G., Dhayal S. G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell. Biochem. Pharmacol. 2009, 78:1419-1427.
22. Shah U. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders. Curr. Opin. Drug Discov. Devel. 2009, 12:519-532.